Suggestions

Du même auteur

Time to next treatment or death as a candidate surrogate endpoint for overall survival in advanced melanoma patients treated with immune checkpoint inhibitors: an insight from the phase III CheckMate 067 trial

Archive ouverte | Branchoux, S. | CCSD

International audience. BACKGROUND: Time to next treatment or death (TNT-D) may be a patient-relevant endpoint in patients treated with immune checkpoint inhibitors. This study investigated TNT-D as a surrogate endp...

PCN214 COST-EFFECTIVENESS ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS SUNITINIB FOR THE FIRST-LINE TREATMENT OF INTERMEDIATE- TO POOR-RISK ADVANCED RENAL CELL CARCINOMA IN FRANCE

Archive ouverte | Branchoux, S. | CCSD

International audience. ObjectivesNivolumab in combination with ipilimumab (NIVO+IPI) is the first immuno-oncology combination to demonstrate significant, long-term overall survival (OS) benefit in previously untrea...

Exploring the Health-Related Quality of Life of Patients Treated With Immune Checkpoint Inhibitors: Social Media Study

Archive ouverte | Cotte, F. E. | CCSD

International audience. Background: Immune checkpoint inhibitors (ICIs) are increasingly used to treat several types of tumors. Impact of this emerging therapy on patients’ health-related quality of life (HRQoL) is ...

Chargement des enrichissements...